[Significance of the examination of path between eosinophils in peripheral blood and marrow stem cells for evaluating the effect of hormone therapy in patients with allergic rhinitis].
OBJECTIVE
By means of the detection of the numbers of CD34(+) cells and eosinophils (EOS), and the level of IL-5 in peripheral blood from normal controls and patients with allergic rhinitis pre- or post-treatment, the role of EOS-stem cells paths for treatment effect in allergic rhinitis (AR) was studied so as to find the convenient and quick indicators which could be used to evaluate the clinical therapeutic effect and adjust the methods of the hormone therapy.


METHODS
There were 2 groups. (1) experimental group: 44 patients, including 24 males and 20 females with a age range of 7 to 68 years old. The patients received the treatment of fluticasone spurt for four weeks. (2) CONTROL GROUP: 30 cases, from normal health examination. The EOS numbers, CD4(+) cell numbers and the IL-5 level were examined in control group as well as before and after therapy in experimental group.


RESULTS
The IL-5 level and CD numbers before therapy in experimental group were (88.25 +/- 33.47) ng/L, (9.24 +/- 2.15)/10(5), significantly higher than that after therapy and experimental group which were (44.34 +/- 16.32) ng/L, (6.31 +/- 1.83)/10(5) and (31.24 +/- 8.43) ng/L, (3.47 +/- 1.32)/10(5) respectively. The IL-5 level was positively correlated with the CD34(+) number pre-and post treatment in experimental group (r = 0.64, P <0.01; (r = 0.61, P <0.01). The EOS number was positively correlated with the level of IL-5 (r = 0.64, P <0.01).


CONCLUSIONS
IL-5 and CD34(+) cells can be regarded as indicators to evaluate the therapeutic effect. The EOS, CD34(+) cells and the level of IL-5 in the peripheral blood are correlated with the pathogenesis of AR, suggesting that there is a related path between the local nasal tissue of AR patients and the marrow.
Zhang
Hui
H
Department of Otorhinalaryngology, Second Hospital of Shandong University, Jinan 250033, China.
Zhang
Da-Liang
DL
Zhao
Jing-Jie
JJ
Liu
Jun-Li
JL
Fan
Xian-Liang
XL
Guo
Cheng-Hao
CH
D000293:Adolescent; D000328:Adult; D000368:Aged; D000730:Androstadienes / Q000627:therapeutic use*; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D018952:Antigens, CD34 / Q000378:metabolism; D001854:Bone Marrow Cells; D016022:Case-Control Studies; D002648:Child; D004804:Eosinophils / Q000276:immunology*; D005260:Female; D000068298:Fluticasone; D006801:Humans; D015848:Interleukin-5 / Q000097:blood; D008297:Male; D008875:Middle Aged; D012221:Rhinitis, Allergic, Perennial / Q000097:blood* / Q000188:drug therapy*; D013234:Stem Cells; D055815:Young Adult
D000730:Androstadienes; D018926:Anti-Allergic Agents; D018952:Antigens, CD34; D015848:Interleukin-5; D000068298:Fluticasone